The PAA pattern..., page-382

Well, I don’t think Prof MP was wondering where it would go, it will more than likely go where the data held by Elanco, Eli Lilly and the FDA is available, where they are most desperate economically, and have the Deepest pockets. If this is a lot better than Remdesivir as the Professor no doubt thinks/hopes it could be based on that one chart (given it is Monepantel on the chart). The big question is how much? I don’t imagine any company is going to take the time to organise some sort of royalty scheme instead of just buying PAA out.
I know....let’s not count our eggs...